Atherogenic dyslipidemia (hyperlipidemia) includes a triad of metabolic disorders:
- elevated blood levels of small, dense, low-density lipoprotein ( LDL )
- reduction of high density lipoprotein ( HDL )
- increase in triglycerides .
| Atherogenic dyslipidemia | |
|---|---|
| ICD-10 | E 78.9 |
Characteristic of obesity , metabolic syndrome , typical of insulin resistance and type 2 diabetes .
Atherogenic dyslipidemia is an important risk factor for cardiovascular diseases and, in particular, myocardial infarction .
Notes
Literature
- Chapman MJ, Redfern JS, McGovern ME, Giral P. Optimal pharmacotherapy to combat the atherogenic lipid triad. Curr Opin Cardiol. 2011 Sep; 26 (5): 403-11. doi: 10.1097 / HCO.0b013e32834965e9.
- Tenenbaum A, Fisman EZ. Fibrates of anti-dyslipidemic arsenal: a spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012 Oct 11; 11: 125. doi: 10.1186 / 1475-2840-11-125.
- Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol. 2012 Nov; 10 (6): 684-6.
Links
- E.L. Buyerova, OM Drapkina, V.T. Ivashkin. Atherogenic dyslipidemia and liver . Archived June 28, 2012.